126 related articles for article (PubMed ID: 32071352)
1. Impacts of Intralipid on Nanodrug Abraxane Therapy and on the Innate Immune System.
Chen YJ; Tsai CY; Cheng YM; Nieh SW; Yeh TK; Chen CP; Wang MH; Chou LH; Chiu TY; Liu L; Ho C; Chen CT; Liu TW
Sci Rep; 2020 Feb; 10(1):2838. PubMed ID: 32071352
[TBL] [Abstract][Full Text] [Related]
2. A New Approach to Deliver Anti-cancer Nanodrugs with Reduced Off-target Toxicities and Improved Efficiency by Temporarily Blunting the Reticuloendothelial System with Intralipid.
Liu L; Ye Q; Lu M; Chen ST; Tseng HW; Lo YC; Ho C
Sci Rep; 2017 Nov; 7(1):16106. PubMed ID: 29170482
[TBL] [Abstract][Full Text] [Related]
3. Decreased reticuloendothelial system clearance and increased blood half-life and immune cell labeling for nano- and micron-sized superparamagnetic iron-oxide particles upon pre-treatment with Intralipid.
Liu L; Hitchens TK; Ye Q; Wu Y; Barbe B; Prior DE; Li WF; Yeh FC; Foley LM; Bain DJ; Ho C
Biochim Biophys Acta; 2013 Jun; 1830(6):3447-53. PubMed ID: 23396002
[TBL] [Abstract][Full Text] [Related]
4. A paclitaxel-loaded recombinant polypeptide nanoparticle outperforms Abraxane in multiple murine cancer models.
Bhattacharyya J; Bellucci JJ; Weitzhandler I; McDaniel JR; Spasojevic I; Li X; Lin CC; Chi JT; Chilkoti A
Nat Commun; 2015 Aug; 6():7939. PubMed ID: 26239362
[TBL] [Abstract][Full Text] [Related]
5. An imagable and photothermal "Abraxane-like" nanodrug for combination cancer therapy to treat subcutaneous and metastatic breast tumors.
Chen Q; Liang C; Wang C; Liu Z
Adv Mater; 2015 Feb; 27(5):903-10. PubMed ID: 25504416
[TBL] [Abstract][Full Text] [Related]
6. Antibody-Targeted Chemotherapy for the Treatment of Melanoma.
Nevala WK; Buhrow SA; Knauer DJ; Reid JM; Atanasova EA; Markovic SN
Cancer Res; 2016 Jul; 76(13):3954-64. PubMed ID: 27197186
[TBL] [Abstract][Full Text] [Related]
7. Co-delivery of Pirarubicin and Paclitaxel by Human Serum Albumin Nanoparticles to Enhance Antitumor Effect and Reduce Systemic Toxicity in Breast Cancers.
Yi X; Lian X; Dong J; Wan Z; Xia C; Song X; Fu Y; Gong T; Zhang Z
Mol Pharm; 2015 Nov; 12(11):4085-98. PubMed ID: 26422373
[TBL] [Abstract][Full Text] [Related]
8. Lipid Emulsion Containing High Amounts of n3 Fatty Acids (Omegaven) as Opposed to n6 Fatty Acids (Intralipid) Preserves Insulin Signaling and Glucose Uptake in Perfused Rat Hearts.
Lou PH; Lucchinetti E; Hersberger M; Clanachan AS; Zaugg M
Anesth Analg; 2020 Jan; 130(1):37-48. PubMed ID: 31274599
[TBL] [Abstract][Full Text] [Related]
9. Novel paclitaxel formulations solubilized by parenteral nutrition nanoemulsions for application against glioma cell lines.
Najlah M; Kadam A; Wan KW; Ahmed W; Taylor KM; Elhissi AM
Int J Pharm; 2016 Jun; 506(1-2):102-9. PubMed ID: 27107899
[TBL] [Abstract][Full Text] [Related]
10. Targeting of albumin-embedded paclitaxel nanoparticles to tumors.
Karmali PP; Kotamraju VR; Kastantin M; Black M; Missirlis D; Tirrell M; Ruoslahti E
Nanomedicine; 2009 Mar; 5(1):73-82. PubMed ID: 18829396
[TBL] [Abstract][Full Text] [Related]
11. Antibody-nanoparticle conjugate constructed with trastuzumab and nanoparticle albumin-bound paclitaxel for targeted therapy of human epidermal growth factor receptor 2-positive gastric cancer.
Xiong J; Han S; Ding S; He J; Zhang H
Oncol Rep; 2018 Mar; 39(3):1396-1404. PubMed ID: 29328489
[TBL] [Abstract][Full Text] [Related]
12. Cerium oxide nanoparticles exert antitumor effects and enhance paclitaxel toxicity and activity against breast cancer cells.
Atlı Şekeroğlu Z; Şekeroğlu V; Aydın B; Kontaş Yedier S
J Biomed Mater Res B Appl Biomater; 2023 Mar; 111(3):579-589. PubMed ID: 36221929
[TBL] [Abstract][Full Text] [Related]
13. Layer-by-layer assembly of hierarchical nanoarchitectures to enhance the systemic performance of nanoparticle albumin-bound paclitaxel.
Ruttala HB; Ramasamy T; Shin BS; Choi HG; Yong CS; Kim JO
Int J Pharm; 2017 Mar; 519(1-2):11-21. PubMed ID: 28069389
[TBL] [Abstract][Full Text] [Related]
14. IF7-Conjugated Nanoparticles Target Annexin 1 of Tumor Vasculature against P-gp Mediated Multidrug Resistance.
Yu DH; Liu YR; Luan X; Liu HJ; Gao YG; Wu H; Fang C; Chen HZ
Bioconjug Chem; 2015 Aug; 26(8):1702-12. PubMed ID: 26076081
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel-loaded PCL-TPGS nanoparticles: in vitro and in vivo performance compared with Abraxane®.
Bernabeu E; Helguera G; Legaspi MJ; Gonzalez L; Hocht C; Taira C; Chiappetta DA
Colloids Surf B Biointerfaces; 2014 Jan; 113():43-50. PubMed ID: 24060929
[TBL] [Abstract][Full Text] [Related]
16. DCE-MRI-Derived Parameters in Evaluating Abraxane-Induced Early Vascular Response and the Effectiveness of Its Synergistic Interaction with Cisplatin.
Sun X; Yang L; Yan X; Sun Y; Zhao D; Ji Y; Wang K; Chen X; Shen B
PLoS One; 2016; 11(9):e0162601. PubMed ID: 27632532
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel-Loaded TPGS-b-PCL Nanoparticles: In Vitro Cytotoxicity and Cellular Uptake in MCF-7 and MDA-MB-231 Cells versus mPEG-b-PCL Nanoparticles and Abraxane®.
Bernabeu E; Gonzalez L; Legaspi MJ; Moretton MA; Chiappetta DA
J Nanosci Nanotechnol; 2016 Jan; 16(1):160-70. PubMed ID: 27398441
[TBL] [Abstract][Full Text] [Related]
18. Unraveling the role of Intralipid in suppressing off-target delivery and augmenting the therapeutic effects of anticancer nanomedicines.
Islam R; Gao S; Islam W; Šubr V; Zhou JR; Yokomizo K; Etrych T; Maeda H; Fang J
Acta Biomater; 2021 May; 126():372-383. PubMed ID: 33774199
[TBL] [Abstract][Full Text] [Related]
19. 18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy.
Sun X; Yan Y; Liu S; Cao Q; Yang M; Neamati N; Shen B; Niu G; Chen X
J Nucl Med; 2011 Jan; 52(1):140-6. PubMed ID: 21149494
[TBL] [Abstract][Full Text] [Related]
20. Low dose Intralipid resuscitation improves survival compared to ClinOleic in propranolol overdose in rats.
Macala KF; Khadaroo RG; Panahi S; Gragasin FS; Bourque SL
PLoS One; 2018; 13(8):e0202871. PubMed ID: 30161186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
